Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling - 14/03/20
páginas | 12 |
Iconografías | 8 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Quercetin acts as a RIG-I agonist. |
• | Quercetin treatment united RIG-I, IFN-I and JAK1-STAT1 into a positive-feedback loop which could enlarge the anti-tumor efficacy. |
• | Quercetin shows its potential as an alternative therapeutic approach in melanoma. |
Abstract |
Melanoma is a life-threatening cancer with limited treatments. Retinoic acid-inducible gene I (RIG-I) is a cytosolic pattern recognition receptor (PRR) crucial to RNA virus sensing, interferon production, and tumor suppression. Quercetin, a natural flavonoid, has particularly therapeutic interests to prevent and treat cancer, for its pharmacological effects against oxidant, inflammation, and angiogenesis. Quercetin was investigated for its anti-melanoma activity and potential mechanisms in this study. We found that quercetin inhibited mouse melanoma growth in vivo, and suppressed proliferation and promoted apoptosis of both B16 and A375 cells in vitro. Quercetin upregulated IFN-α and IFN-β expression through activating RIG-I promoter in B16 cells. The induction of IFN-α and IFN-β, which could be severely impaired by silencing RIG-I induced interferon stimulated genes (ISGs). Moreover, RIG-I likely amplifies antitumor effects by activating signal transduction and activator of transcription 1 (STAT1) in the IFN-JAK-STAT pathway in an autocrine and paracrine manner. Our study provided novel insights regarding biological and anti-proliferative activities of quercetin against melanoma, and we identified RIG-I as a potential target in anti-tumor therapies.
El texto completo de este artículo está disponible en PDF.Abbreviations : PRR, RIG-I, IFN-I, IRF3, IRF7, qPCR, CMC-Na, ISGs, TRAIL, PML, MX1, STAT1
Keywords : Quercetin, Melanoma, RIG-I, IFN-I, Anti-tumor
Esquema
Vol 125
Artículo 109984- mai 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?